Results 231 to 240 of about 1,056,606 (342)

Rational antipsychotic polypharmacy in psychotic and bipolar disorders: A focus on D2 receptor partial agonists. [PDF]

Ment Health Clin
Salwan A.
europepmc   +1 more source

Effect of a Calcium Antagonist on Renal Hemodynamics in Salt-loaded Spontaneously Hypertensive Rats.

, 1995
Tatsuo Shimosawa, Katsuyuki Ando, Toshiro Fujita   +2 more
openalex   +2 more sources

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

<i>MCP-1/CCR2</i> axis regulates M2 macrophage polarization and immunosuppression in mycobacterium tuberculosis. [PDF]

Front Immunol
Zhao G, Guo C, Li X, Tan L, Chen X, Tian F, Zhang L, Wang X, Cui J.   +8 more
europepmc   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Letter to the Editor in Response to "Efficacy and Safety of Histamine H3 Receptor Antagonist/Inverse Agonist Including Betahistine for Schizophrenia: A Systematic Review and Meta-Analysis" by Nishii et al. [PDF]

Neuropsychopharmacol Rep
Farhan M.
europepmc   +1 more source

Antagonistic Cross-talk between Rac and Cdc42 GTPases Regulates Generation of Reactive Oxygen Species [PDF]

, 2004
Becky A. Diebold, Bruce Fowler, Justine Lu, Mary C. Dinauer, Gary Bokoch   +4 more
openalex   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Progestin primed ovarian stimulation yields comparable outcomes to the GnRH antagonist protocol for controlled ovarian hyperstimulation. [PDF]

Sci Rep
Meseci E, Okten SB, Bilgen S, Ozveri H, Ocal N, Ozdemir B, Fıcıcıoglu C.   +6 more
europepmc   +1 more source

Evaluation and development of nitric oxide radical scavenging substances (NO· antagonists)

, 1997
Masahiro Kohno, Sakiko Nishibayashi, Norio Ogawa   +2 more
openalex   +1 more source